Royalty Pharma plc Payments of Debt Issuance Costs
Royalty Pharma plc (RPRX) reported Payments of Debt Issuance Costs of $2.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-05
- Royalty Pharma plc payments of debt issuance costs for the quarter ending 2025-12-31 was $3.02M, a 906.67% increase year-over-year.
- Royalty Pharma plc payments of debt issuance costs for the quarter ending 2025-09-30 was $13.54M, a 338.57% increase year-over-year.
- Royalty Pharma plc payments of debt issuance costs for the quarter ending 2024-12-31 was $300.00K, a 81.20% decline year-over-year.
- Royalty Pharma plc payments of debt issuance costs for the quarter ending 2024-09-30 was $3.09M.
- Royalty Pharma plc payments of debt issuance costs for fiscal 2025 was $16.56M, a 31.29% increase from fiscal 2024.
- Royalty Pharma plc payments of debt issuance costs for fiscal 2024 was $12.62M, a 690.48% increase from fiscal 2023.
- Royalty Pharma plc payments of debt issuance costs for fiscal 2023 was $1.60M, a 18.49% increase from fiscal 2022.
- Royalty Pharma plc payments of debt issuance costs for fiscal 2022 was $1.35M, a 89.67% decline from fiscal 2021.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.46M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $16.56M derived: sum of 2 quarters · filed 2026-02-11 | $16.56M 10-K · filed 2026-02-11 | |
| 2025-09-30 | $13.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.54M 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.39M derived: sum of 2 quarters · filed 2026-02-11 | $12.62M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $12.32M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $9.23M 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.60M derived: sum of 2 quarters · filed 2026-02-11 | $1.60M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.35M 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $801.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $13.05M derived: sum of 2 quarters · filed 2024-02-15 | $13.05M derived: sum of 3 quarters · filed 2024-02-15 | $13.05M 10-K · filed 2024-02-15 |
| 2021-09-30 | $12.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $12.24M derived: sum of 2 quarters · filed 2022-11-08 | $12.24M 10-Q · filed 2022-11-08 | $12.40M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $151.00K derived: sum of 3 quarters · filed 2023-02-15 | $37.90M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $151.00K derived: sum of 2 quarters · filed 2023-02-15 | $37.90M derived: sum of 3 quarters · filed 2023-02-15 | $38.87M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $37.90M derived: sum of 2 quarters · filed 2023-02-15 | $38.87M derived: sum of 3 quarters · filed 2023-02-15 | $46.72M 10-K · filed 2023-02-15 |
| 2020-09-30 | $37.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $38.72M derived: sum of 2 quarters · filed 2021-11-10 | $46.56M 10-Q · filed 2021-11-10 | $46.56M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $978.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $8.82M 10-Q · filed 2021-08-11 | $8.82M derived: sum of 3 quarters · filed 2022-02-15 | $8.82M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $7.84M 10-Q · filed 2021-05-11 | $7.84M derived: sum of 2 quarters · filed 2022-02-15 | $7.84M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $2.05M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |